Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

FranceBack to France

Clinical trials in Bois-Guillaume

671 clinical trials in Bois-Guillaume, France across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

FranceOur site in FranceEssaisCliniques.fr(opens in a new tab)
Bois-Guillaume at a glance
671
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

671 trials in Bois-Guillaume

Open in trial search

Papulopustular rosacea

Recruiting

Efficacy and safety of remibrutinib (LOU064) in adult patients with papulopustular rosacea: a randomized, double‑blind, placebo‑controlled Phase 2 trial

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Remibrutinib
  • Sponsor:Novartis Pharma AG

Chronic kidney disease

Recruiting

Phase III Randomized Study of Balcinrenone and Dapagliflozin Versus Dapagliflozin on Renal and Cardiovascular Outcomes in Patients with Chronic Kidney Disease Stage 3b‑4

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Balcinrenone
  • Sponsor:AstraZeneca AB

Dermatitis atopic

Recruiting

Efficacy and Safety of Lebrikizumab in Adults and Adolescents with Moderate-to-Severe Face and Neck Atopic Dermatitis

Registered drug
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Lebrikizumab
  • Sponsor:Almirall S.A.

Hidradenitis

Recruiting

Long-term Safety and Efficacy of Remibrutinib in Adults with Moderate to Severe Hidradenitis Suppurativa

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Remibrutinib
  • Sponsor:Novartis Pharma AG

Primary progressive multiple sclerosis

Recruiting

Orelabrutinib in Patients with Primary Progressive Multiple Sclerosis

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Orelabrutinib
  • Sponsor:Zenas Biopharma (USA) LLC

Chronic spontaneous urticaria

Recruiting

A study to evaluate the long-term safety and effectiveness of barzolvolimab in patients with chronic spontaneous urticaria

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Epinephrine
  • Sponsor:Celldex Therapeutics Inc.

Secondary progressive multiple sclerosis

Recruiting

A study to evaluate the effectiveness and safety of remibrutinib in patients with secondary progressive multiple sclerosis

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Remibrutinib
  • Sponsor:Novartis Pharma AG

Cardiovascular disorder+1

Recruiting

Study of Zilebesiran Added to Standard Treatment to Reduce Heart Problems in Adults with High Blood Pressure and Heart Disease Risk

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Zilebesiran
  • Sponsor:Alnylam Pharmaceuticals Inc.

Vitiligo+2

Recruiting

Long-term safety study of oral povorcitinib in patients with hidradenitis suppurativa, prurigo nodularis, or vitiligo who previously participated in clinical trials

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Povorcitinib
  • Sponsor:Incyte Corp.

Hormone receptor positive HER2 negative breast cancer

Recruiting

Study of personalized treatment using drug combination therapy for young women with early stage hormone receptor-positive breast cancer based on gene expression testing

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years
  • Substances:Anastrozole
  • Sponsor:Unicancer

Arteriosclerosis

Recruiting

Study of laroprovstat (AZD0780) to reduce heart attack, stroke and vascular complications in patients with atherosclerotic cardiovascular disease or high risk of developing it

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Laroprovstat
  • Sponsor:AstraZeneca AB

Chronic kidney disease+1

Recruiting

Study on the Effects of Baxdrostat and Dapagliflozin in Adults with Chronic Kidney Disease and High Blood Pressure

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Baxdrostat
  • Sponsor:AstraZeneca AB

Other cities in France

The busiest research cities in the country

All 366 cities in France

Clinical research in Bois-Guillaume

What the registry says about research in the country

01 Kidney Disease & Transplantation

Innovative research focusing on chronic kidney disease treatments and transplant outcomes, including studies of novel medications like baxdrostat and tegoprubart for improving patient care.

  • Kidney Transplant Rejection Prevention
  • CKD Management
  • Hypertension Control

Multiple trials evaluating new therapeutic approaches for transplant recipients and CKD patients.

02 Blood Disorders

Clinical investigations into treatments for various blood-related conditions, with emphasis on immune thrombocytopenia and thrombotic disorders.

  • Thrombotic Thrombocytopenic Purpura
  • Hemolytic Uremic Syndrome
  • Immunological Therapies

Advanced studies combining established and experimental treatments for better patient outcomes.

03 Infectious Disease Management

Research examining treatment strategies for viral infections and optimization of antibiotic therapy, particularly in elderly populations.

  • Cytomegalovirus Treatment
  • Antibiotic Management
  • Viral Pneumonia

Studies focused on improving treatment protocols and reducing antibiotic overuse.

04 Autoimmune Conditions

Investigation of novel therapies for vasculitis and related autoimmune disorders, including targeted biological treatments.

  • Takayasu Arteritis
  • ANCA-Associated Vasculitis
  • Goodpasture Disease

Evaluating new treatment combinations to improve disease management and patient outcomes.

Back to FranceAll countries
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.